Grail's Galleri multi-cancer test misses primary endpoint in NHS study, fueling skepticism
TL;DR Summary
Grail's Galleri blood test for early cancer detection failed to meet its primary endpoint in a large NHS-backed study, renewing questions about its clinical utility despite some detected benefits. Grail reported selling 185,000 tests in 2025 for $136.8 million, and its stock fell about 47% after hours following the setback.
- Key study of Grail’s cancer detection test fails in setback for company statnews.com
- GRAIL Q4 Earnings Call Highlights Yahoo Finance
- Grail shares plunge on mixed cancer trial data and steep losses Investing.com
- GRAL Stock Slumps 48% After Hours As Trial For Cancer Test Fails To Show Reduction In Late-Stage Diagnoses Stocktwits
- GRAL: Strong commercial growth and positive trial results drive optimism for 2026 and beyond TradingView
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
90%
514 → 50 words
Want the full story? Read the original article
Read on statnews.com